Crossmark

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab

Crossref DOI link: https://doi.org/10.1016/j.reumae.2020.06.008

Published Print: 2021-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Figuero-Pérez, Luis

Olivares-Hernández, Alejandro

Escala-Cornejo, Roberto A.

Terán-Brage, Eduardo

López-Gutiérrez, Álvaro

Cruz-Hernández, Juan J.
License Information

Text and Data Mining valid from 2021-12-01
More Information

This article is maintained by: Elsevier

Article Title: Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2020.06.008

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2020.06.003

Content Type: article

Copyright: © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.